TMPRSS2 and prostate carcinoma: The combination of rucaparib with radiation therapy was synergistic for prostate cancer cells expressing the TMPRSS2:ERG gene fusion, as these cells showed enhanced sensitivity towards rucaparib, which increased radiation response [39].